Market Overview

UPDATE: Bank of America Initiates Coverage on Myriad Genetics

Share:
Related MYGN
Myriad Announces Favorable Medicare Final Coverage Decision for the ProlarisR) Test
Tuesday's After-Hours Movers Led By Fossil, Cree And Myriad

According to a research report published this morning, Bank of America has initiated Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and $28 PT.

Bank of America said in the report, "We reinstate Myriad Genetics (MYGN), a leading molecular diagnostics company, with a Neutral rating and $28 price objective. While we are positive about Myriad's initiatives to bolster near-to-midterm sales, we have some reservations about Myriad's long-term growth as its flagship product, BRACAnalysis, matures."

Myriad Genetics closed yesterday at $25.75.

Latest Ratings for MYGN

DateFirmActionFromTo
Aug 2015Wells FargoUpgradesMarket PerformOutperform
Aug 2015JMP SecuritiesMaintainsMarket Outperform
May 2015JMP SecuritiesMaintainsMarket Outperform

View More Analyst Ratings for MYGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (MYGN)

Get Benzinga's Newsletters